Publication Name	World Journal of Clinical Cases
Manuscript ID	74195
Country	China

Received	2021-12-20 12:35
Peer-Review Started	2021-12-20 12:37
To Make the First Decision
Return for Revision	2022-04-08 00:24
Revised	2022-04-17 09:30
Second Decision	2022-05-30 02:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-06-03 21:19
Articles in Press	2022-06-03 21:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-07-03 08:47
Publish the Manuscript Online	2022-07-11 08:36

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Case Report
Article Title	Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Cang-Jian Zhang, Jun-Yu Zhang, Lin-Jie Li and Neng-Wen Xu
ORCID	Author(s) ORCID Number Cang-Jian Zhang http://orcid.org/0000-0001-8966-3545 Jun-Yu Zhang http://orcid.org/0000-0002-1013-8172 Lin-Jie Li http://orcid.org/0000-0003-2674-2996 Neng-Wen Xu http://orcid.org/0000-0002-9543-8990
Funding Agency and Grant Number
Corresponding Author	Jun-Yu Zhang, Doctor, Chief Doctor, Department of Hematopathology, Lishui Municipal Central Hospital, No. 289 Kuocang Road, Lishui 323000, Zhejiang Province, China. zhangjunyu815@163.com
Key Words	Refractory diffuse large B-cell lymphoma; Programmed cell death protein-1 inhibitor; Chimeric antigen receptor T cells; Case report
Core Tip	Primary testicular diffuse large B-cell lymphoma (DLBCL) is an uncommon extranodal disease of lymphomas. Refractory DLBCL responds poorly to other lines of chemotherapy, and is associated with short-term survival. Herein, we report one rare case of chimeric antigen receptor T cells (CAR-T) combined with programmed cell-death protein-1 (PD-1) inhibitor to treat refractory DLBCL in a 41-year-old male. Our findings support the potential benefit of CAR-T combined with PD-1 inhibitor therapies in this type of refractory DLBCL.
Publish Date	2022-07-11 08:36
Citation	Zhang CJ, Zhang JY, Li LJ, Xu NW. Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report. World J Clin Cases 2022; 10(21): 7502-7508
URL	https://www.wjgnet.com/2307-8960/full/v10/i21/7502.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i21.7502

Full Article (PDF)	WJCC-10-7502.pdf
Full Article (Word)	WJCC-10-7502.docx
CARE Checklist–2016	74195-CARE-Checklist–2016-revision.pdf
Manuscript File	74195_Auto_Edited-LS.docx
Answering Reviewers	74195-Answering reviewers.pdf
Audio Core Tip	74195-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	74195-Conflict-of-interest statement.pdf
Copyright License Agreement	74195-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	74195-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	74195-Language certificate.pdf
Peer-review Report	74195-Peer-review(s).pdf
Scientific Misconduct Check	74195-Bing-Fan JR-2.png
Scientific Editor Work List	74195-Scientific editor work list.pdf
CrossCheck Report	74195-CrossCheck report.pdf
CrossCheck Report	74195-CrossCheck.png